These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21426298)

  • 1. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
    Sartor AO
    J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New treatments for castration-resistant prostate cancer].
    Sautois B; Gennigens C
    Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
    Lheureux S; Joly F
    Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Dyer M; Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current clinical trials in castrate-resistant prostate cancer.
    Petrylak DP
    Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Oudard S
    Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
    Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
    PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.